- Exchange: SIX Swiss Ex
- Sector: Consumer, Non-cyclical
- Industry: Pharmaceuticals
- Sub-Industry: Drug Delivery Systems
Cosmo Pharmaceuticals SpA
+ Add to WatchlistCOPN:SW
51.00 CHF 0.95 1.83%As of 11:43:47 ET on 05/21/2013.
Snapshot for Cosmo Pharmaceuticals SpA (COPN)
| Open: | 52.00 | Day's Range: | 50.80 - 52.35 | Volume: | 20,977 |
|---|---|---|---|---|---|
| Previous Close: | 51.95 | 52wk Range: | 21.50 - 52.35 | 1-Yr Rtn: | +104.00% |
Key Statistics for COPN
| Current P/E Ratio (ttm) | 28.6714 |
|---|---|
| Estimated P/E(12/2013) | 46.8937 |
| Relative P/E vs. SMI | 1.3969 |
| Earnings Per Share (EUR) (ttm) | 1.4230 |
| Est. EPS (EUR) (12/2013) | 0.8700 |
| Est. PEG Ratio | - |
| Market Cap (M CHF) | 764.78 |
| Shares Outstanding (M) | 15.00 |
| 30 Day Average Volume | 10,765 |
| Price/Book (mrq) | 4.5855 |
| Price/Sale (ttm) | 9.3143 |
| Dividend Indicated Gross Yield | -% |
| Cash Dividend | - |
| Last Dividend | |
| 5 Year Dividend Growth | - |
| Next Earnings Announcement | 08/01/2013 |
mrq = Most Recent Quarter; ttm = Trailing Twelve Months
Income Statement for COPN
Company Profile & Key Executives for COPN
Cosmo Pharmaceuticals SpA develops and manufactures therapies for gastrointestinal diseases. The Company's proprietary technology delays the delivery of the active drug mainly into the lumen of the colon. Cosmo develops treatments for inflammatory bowel diseases such as ulcerative colitis and Crohn's disease, and for colon infections.
| Mauro Severino AjaniChairman/CEO/Founder | Hans Christoph TannerChief Financial Officer |
| Marco LecchiDeputy Chief Financial Officer | Guiseppe CiprianoChief Operating Officer |
Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.
Sponsored Financial Commentaries
Advertisement
Top Forex Trading Resources
-
COPN News
-
Industry News
Advertisement
Advertisement
Sponsored Links
Advertisements
Rate this Page